(Nevada, Las Vegas) United States, DelveInsight’s, “Atopic Dermatitis – Pipeline Insight, 2023,” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Hemophilia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Atopic Dermatitis Pipeline Report
-
Over 80+ companies and 80+ pipeline drugs in the Alpha1-Antitrypsin Deficiency (AATD) pipeline landscape and their anticipated acceptance in the Hemophilia market would significantly increase market revenue.
-
Leading Hemophilia companies developing novel drug candidates to improve the Hemophilia treatment landscape include Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics
-
Promising Hemophilia pipeline therapies in various stages of development include SerpinPC, Fitusiran, ASC 618, and many others
Atopic Dermatitis Overview
Atopic dermatitis also called eczema, is a chronic condition and the most common type of skin inflammation that usually starts in early childhood, but can occur at any age and can be recurrent or persistent throughout life. In the word ‘dermatitis,’ ‘derm’ means ‘skin’, and ‘itis’ means ‘inflammation.’ Thus, dermatitis is a skin inflammation characterized by itchiness, redness, and a rash caused by genetics, an overactive immune system, infections, allergies, and irritating substances. Half of the patients with moderate-to-severe eczema also have asthma, hay fever (allergic rhinitis), and food allergies. It is the most common chronic skin disease in children.
Atopic Dermatitis Pipeline Analysis: Drug Profile
Tapinarof: Dermavant Sciences
Tapinarof is a therapeutic aryl hydrocarbon receptor modulating agent (TAMA) that binds and activates the aryl hydrocarbon receptor in multiple cell types, including cells of the target tissue-human skin. Tapinarof has also shown to moderate proinflammatory cytokine expression in stimulated peripheral blood CD4+ T cells and ex vivo human skin, and impact barrier gene expression in primary human keratinocytes. The drug is currently being evaluated in the Phase III stage of development for the treatment of patients with Atopic dermatitis.
Etrasimod: Pfizer
Etrasimod is an oral, once daily, selective sphingosine-1-phosphate (S1P) receptor modulator designed for optimized pharmacology and engagement of S1P receptors 1, 4, and 5. In addition to UC, it is being investigated for a range of other immuno-inflammatory diseases and is in Phase II/III stage of development for the treatment of patients with Atopic dermatitis.
Discover more about the emerging Atopic Dermatitis drugs @ Atopic Dermatitis Treatment Drugs
Atopic Dermatitis Pipeline Therapies and Key Companies
-
Tapinarof: Dermavant Sciences
-
Etrasimod: Pfizer
-
B244: AOBiome
-
Lirentelimab: Allakos Inc
-
QY201: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
And many others
Atopic Dermatitis Pipeline Therapeutics Assessment
DelveInsight’s Report covers around 110 + products under different phases of clinical development like
-
Late stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued and inactive candidates
Alpha1-Antitrypsin Deficiency (AATD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Oral
-
Intravenous
-
Subcutaneous
-
Parenteral
-
Topical
Molecule Type
Products have been categorized under various Molecule types such as
-
Recombinant fusion proteins
-
Small molecule
-
Monoclonal antibody
-
Peptide
-
Polymer
-
Gene therapy
Product Type
Drugs have been categorized under various product types like Mono, Combination, and Mono/Combination.
Drugs have been categorized under various product types like mono, Combination, and Mono/Combination.
Scope of the Atopic Dermatitis Pipeline Report
-
Coverage: Global
-
Key Alpha1 Antitrypsin Deficiency Companies: Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics
-
Key Atopic Dermatitis Pipeline Therapies: Tapinarof, Etrasimod, B244, Lirentelimab, QY201 and many others
Find out more about the Atopic Dermatitis treatment options in development @ Atopic
Table of Contents
1. Atopic Dermatitis Introduction
2. Atopic Dermatitis Executive Summary
3. Atopic Dermatitis Overview
4. Atopic Dermatitis Pipeline Therapeutics
5. Hemophilia Late-Stage Products (Phase III)
6. Hemophilia Mid-Stage Products (Phase II)
7. Hemophilia Early Stage Products (Phase I/II)
8. Atopic Dermatitis Preclinical Stage Products
9. Atopic Dermatitis Discovery Stage Products
10. Atopic Dermatitis Therapeutic Assessment
11. Atopic Dermatitis Inactive Products
12. Atopic Dermatitis Collaborations Assessment- Licensing / Partnering / Funding
13. Atopic Dermatitis Unmet Needs
14. Atopic Dermatitis Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services